TY - JOUR
KW - Humans
KW - Male
KW - Female
KW - *Hepatic Encephalopathy/diagnosis/epidemiology/etiology
KW - Cohort Studies
KW - Liver Cirrhosis/complications/diagnosis/epidemiology
KW - Risk Factors
KW - Fibrosis
KW - United Kingdom/epidemiology
AU - B. Jones
AU - C. Jenkins
AU - D. Murphy
AU - J. Orr
AU - A. Yeoman
AU - E. Hubbuck
AU - B. Heywood
AU - C. Currie
AD - Global Pharmacoepidemiology, Human Data Sciences, Cardiff, UK.
Market Access and Government Affairs, Norgine Pharmaceuticals Limited, Uxbridge, UK.
Gwent Liver Unit, Hepatology Department, University Hospitals Bristol and Weston, Bristol, UK.
Gwent Liver Unit, Aneurin Bevan University Health Board, Royal Gwent Hospital, Newport, Wales, UK.
Institute of Population Health, School of Medicine, Cardiff University, Cardiff, UK.
AN - 37930150
BT - Hepatol Commun
C2 - PMC10629733 with the CanSense Group. Daniel Murphy is employed by Norgine Ltd. Bethan I. Jones, Ellen R. Hubbuck, and Cerys A. Jenkins are employed by, and Craig J. Currie is a director of Pharmatelligence Limited (trading as Human Data Sciences), a research consultancy receiving funding from Norgine Pharmaceuticals Limited for the submitted work. The remaining authors have no conflicts to report.
DO - 10.1097/hc9.0000000000000307
DP - NLM
ET - 2023/11/06
LA - eng
M1 - 11
N1 - 2471-254x
Jones, Bethan I
Orcid: 0000-0003-1954-9362
Jenkins, Cerys A
Orcid: 0000-0002-3719-7463
Murphy, Daniel
Orcid: 0000-0001-6155-884
Orr, James
Yeoman, Andrew
Hubbuck, Ellen R
Orcid: 0000-0001-8543-8455
Heywood, Ben R
Orcid: 0009-0006-8426-3271
Currie, Craig J
Orcid: 0000-0002-6154-818
Journal Article
Research Support, Non-U.S. Gov't
United States
Hepatol Commun. 2023 Nov 6;7(11):e0307. doi: 10.1097/HC9.0000000000000307. eCollection 2023 Nov 1.
PY - 2023
SN - 2471-254x
T2 - Hepatol Commun
TI - Predicting hepatic encephalopathy in patients with cirrhosis: A UK population-based study and validation of risk scores
VL - 7
ER -